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Abstract
Introduction: Although cetuximab and panitumumab show an increased efficacy for patients with KRAS-NRAS-BRAF and
PI3KCA wild-type metastatic colorectal cancer, primary resistance occurs in a relevant subset of molecularly enriched
populations.
Patients and Methods: We evaluated the outcome of 68 patients with advanced colorectal cancer and RAS, BRAF and
PI3KCA status according to ALK gene status (disomic vs. gain of ALK gene copy number – defined as mean of 3 to 5 fusion
signals in $10% of cells). All consecutive patients received cetuximab and irinotecan or panitumumab alone for
chemorefractory disease.
Results: No ALK translocations or amplifications were detected. ALK gene copy number gain was found in 25 (37%) tumors.
Response rate was significantly higher in patients with disomic ALK as compared to those with gain of gene copy number
(70% vs. 32%; p = 0.0048). Similarly, progression-free survival was significantly different when comparing the two groups (6.7
vs. 5.3 months; p = 0.045). A trend was observed also for overall survival (18.5 vs. 15.6 months; p = 0.885).
Conclusion: Gain of ALK gene copy number might represent a negative prognostic factor in mCRC and may have a role in
resistance to anti-EGFR therapy.
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Introduction
Treatment with anti-epidermal growth factor receptor (EGFR)
monoclonal antibodies - cetuximab and panitumumab - improved
the outcome of patients with advanced KRAS wild-type colorectal
cancer (CRC) in combination with first- or second-line fluoropyr-
imidine-based chemotherapy or in the setting of chemorefractory
disease [1–6].
Several resistance biomarkers beyond KRAS were studied in
order to improve patients selection. It was previously shown that
the response rate to cetuximab reached the value of 41.2% for
patients with KRAS, BRAF, NRAS and exon 20 PI3KCA ‘‘quadruple
wild-type’’ status [7]. However, even in molecularly enriched
populations, there is still a relevant subset of non responders [8].
The identification of additional resistance biomarkers is an unmet
clinical need for anti-EGFR treatment personalization in this
setting.
Anaplastic lymphoma kinase (ALK) is a member of the insulin
receptor family with tyrosine kinase activity, which can activate
signal transduction by ligand binding, gene amplification or
mutation [9]. The discovery of a new potentially relevant
oncogenic event in lung cancer, the EML4-ALK translocation,
and the development of ALK inhibitors with promising results in
preclinical models and randomized clinical trials provides the
rationale for the comprehensive characterization of ALK abnor-
malities in patients with other solid tumors, such as CRC [10,11].
Alterations of ALK may interfere with the biological activity of
EGFR through cross-talk of signaling pathways. In fact, oncogenic
ALK may activate independently downstream pathways including
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the PI3KCA/Akt and RAS-RAF-MAPK, even in presence of EGFR
blockage [12].
The aim of our analysis was to evaluate the role of gain of ALK
gene copy number in terms of the response rate, progression-free
survival (PFS) and overall survival (OS) in patients treated with
irinotecan and cetuximab or panitumumab monotherapy for
advanced, chemorefractory CRC and wild-type RAS-RAF-PI3KCA
status.
Patients and Methods
Patient population
Sixty-eight consecutive patients with histologically proven
metastatic CRC with KRAS, NRAS, BRAF, PI3KCA wild-type
status were prospectively collected from 2007 to 2013 at
‘‘Fondazione IRCCS Istituto Nazionale dei Tumori’’ and were
considered eligible for the present study. Patients received a
combination of cetuximab and irinotecan or panitumumab after
clinical evidence of refractoriness to standard chemotherapy
including fluoropyrimidines, oxaliplatin and irinotecan. The
Institutional Review Board of ‘‘Fondazione IRCCS Istituto
Nazionale dei Tumori’’ approved this study and all subject signed
written informed consent.
Mutational analysis of RAS-RAF-PI3KCA
Formalin-fixed paraffin-embedded tumour tissues were re-
viewed for quality and tumour content. A tissue containing at
least 80% of neoplastic cells was selected for each case.
Macrodissection of 7 mm methylene blue-stained sections allowed
the separation of neoplastic and normal cells. Genomic DNA was
extracted using the Qiamp FFPE DNA kit (Qiagen, Chatsworth,
CA, USA) following the manufacturer’s instructions. Mutational
analysis of KRAS exons 2, 3 and 4 was performed as previously
described [13,14]. KRAS exon 2 status was further confirmed
through a specific mutant enriched polymerase chain reaction
(PCR), known to be a more sensitive approach [15]. BRAF (exon
15), NRAS (exons 2 and 3) and PI3KCA (exons 9 and 20)
mutational analysis was performed by means of PCR using specific
primers previously described [13,15]. The PCR products were
subjected to direct sequencing using an ABI Prism 3500 DX
Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) and
then evaluated by means of the ChromasPro software.
ALK gene copy number status
Three to four mm-thick sections were cut from paraffin blocks
and mounted on positively charged slides and dried at least 1 hour
at 56uC. Tissue sections were deparaffinized in xylene (3 times
each of 10 minutes), rehydrated with an ethanol-to-water series
(100%–85%–70%). Subsequently, the sections were pretreated in
TE (Tris 5 mM-EDTA 1 mM, pH = 7) at 96u for 15 minutes,
rinsed in distilled water and enzymatically digested with pepsin
0,4% in 0.01 N HCl for 6 to 10 minutes at 37uC, with monitoring
of the progression of the enzymatic digestion using a phase
contrast microscope.
Slides were then washed in distilled water for two times each of
5 minutes, dehydrated in 96% ethanol for 3 minutes, air dried.
After application of the probe (ALK FISH DNA Probe, Split
signal Dako) on the area of interest the specimens were
codenatured at 85uC for 1 minute and then hybridized at 37uC
overnight using a Hybridizer (Dako). The following day, coverslips
were removed and slides were immersed in posthybridization
solution 2XSSC/0.3% NP40 (73uC for 2 minutes) subsequently in
2XSSC/0.1% NP40 (1 minute at room temperature) and finally
brifly rinsed in distilled water. The slides were then left to dry in
the dark at room temperature, and nuclei were counterstained in
Vectashild Antifade solution with DAPI (4,6-diamino-2-phenyin-
dole-2-hydrocloride) (Vector Laboratories, Inc. Burlingame CA).
A minimum of 60 non-overlapping nuclei of invasive tumor cells
were scored using Olympus epifluorescence microscope equipped
with an 1006 oil immersion objective and 4,6-diamidino-2-
phenylindole/Spectrum Green/Orange single and triple bandpass
filters. The two DNA probe within ALK FISH DNA Probe, Split
Signal, are designed to hybridize upstream and downstream of the
breakpoint cluster region. Co-localization of the probes results in a
yellow signal, whereas translocation events in the breakpoint
cluster region will split one signal in separate green (fluorescin) and
red (Texas Red) signals. The criteria for ALK translocation
positivity was the presence of the split of the probes in at lest 15%
of cells.
As criteria for copy number aberrations of ALK has not been
established, we arbitrarily used the following cut-offs adapted from
the criteria established for EGFR and HER-2 in non-small cell lung
cancer specimens [16,17]. According to Cappuzzo et al. [16],
patients may be classified into six FISH strata with ascending
number of copies of the EGFR gene per cell according to the
frequency of tumor cells with specific number of copies of the
EGFR gene. In our study, we adopted cut-offs for classifying ALK
gene copy number alterations as previously described for non-
small cell lung cancer [18]. Briefly, gain of ALK gene copy number
(including both low and high genomic gain) was defined as a mean
copy number of 3 to 5 fusion signals in $10% of cells and
amplification as the presence of $6 copies of ALK per cell in
$10% of analyzed cells. In cases where clusters were observed, we
reported the percentage of cells with clusters and considered
amplified cases with $10% of ALK clusters [18] (Figure 1).
Statistical Analysis
Descriptive statistical methodology was used to analyze the
results and qualitative data were compared by chi-square test, as
appropriate.
PFS was defined as the time from date of enrolment to the date
of the first documented progressive disease (PD) or death for any
cause. OS was calculated from date of enrolment to the date of
death due to any cause, or censored at the date of last follow-up for
living patients. Survival curves were plotted by the Kaplan-Meier
method and compared by log-rank test. For ordinal variables, a
log-rank test of trend was applied. Data analysed were using SPSS
version 16.0 for Windows (SPSS, Chicago, IL, USA). Results were
reported with 95% confidence intervals (CI). All the statistical tests
were conducted at the two-sided 0.05 level of significance.
Figure 1. ALK FISH examples. Gain of ALK GCN (including both low
and high genomic gain) was defined as a mean of 3 to 5 fusion signals
in $10% of cells (Figure on right). Disomic cells are shown in Figure on
left.
doi:10.1371/journal.pone.0092147.g001
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Results
Patient population
Sixty-eight consecutive patients with advanced wild-type RAS-
RAF-PI3KCA CRC were included in this prospective dataset at
Fondazione IRCCS Istituto Nazionale dei Tumori of Milan.
Patient and disease characteristics are shown in Table 1 and
summarized in Figure 2. Most of the patients (n = 60, 88%) were
classified as chemorefractory and were previously treated with
both oxaliplatin-based and irinotecan-based chemotherapy, and
after failure of at least two previous lines of chemotherapy.
However, 8 (12%) of patients were considered irinotecan ineligible
and received panitumumab as second-line treatment after failure
of oxaliplatin-based chemotherapy. Overall, we observed a partial
response in 34 patients (50%), and progressive disease in 17 cases
(25%). Additional 17 patients (25%) showed stable disease (SD),
whereas no complete remissions were obtained. Median follow-up
of the whole series was 32.5 months. Overall, 67 patients had a
documented PD, and a total of 41 (60%) patients died. All deaths
were due to PD, while one patient was lost to follow-up. Median
PFS and OS were 6.3 and 16.4 months, respectively. The OS
curves were truncated at 3 years, namely at a time interval slightly
longer than the median follow-up.
Patients outcome according to ALK gene copy number
status
No ALK translocations or amplifications were detected. ALK
gene copy number gain was found in 25 (37%) tumors, with a
median number of ALK signals per cell with abnormal FISH
results was 3.52 (range, 3.0–5.8); disomic ALK status was found in
43 (63%) samples, as shown in Figure 1. Regarding correlation of
ALK status with outcomes, only 8 of 25 (32%) patients in the group
with increased ALK gene copy number showed a partial response
according to RECIST 1.1 criteria [19], while up to 30 of 43 (70%)
patients with disomic ALK status responded. This difference was
statistically significant (p = 0.0048). PFS was significantly worsened
in presence of increased ALK gene copy number vs. disomic ALK
status (5.3 vs. 6.7 months; Hazard Ratio [HR] = 1.759, 95% CI,
1.013–3.053; p = 0.045; Figure 3). OS was slightly worsened in
patients with increased ALK gene copy number, although this
difference did not reach statistical significance (15.6 vs. 18.5
months; HR = 1.181, 95% CI, 0.623–1.738; p = 0.885; Figure 4).
Discussion
International guidelines recommend KRAS mutation testing
prior to prescribing anti-EGFR the monoclonal antibodies
cetuximab and panitumumab for patients with advanced CRC
and state that alternative therapy should be prescribed when
mutations are detected [20]. In fact, KRAS mutations have been
validated as predictive biomarkers of resistance to anti-EGFR
treatment [4–7]. However, a significant percentage of patients
with wild-type KRAS tumors fails to respond to treatment.
Therefore, the identification of additional biomarkers to drive
‘‘negative’’ selection of patients with advanced CRC is an unmet
clinical need. A more accurate treatment personalization may help
to avoid unnecessary toxicity and sociosanitary costs for patients
who will not benefit from treatment. Most biological factors
analyzed in the attempt to improve patient selection in this setting
focused either on the EGFR downstream signalling pathway or on
the receptor itself. Recently, a broader mutation testing of RAS
gene (at exons 2, 3, or 4 of both KRAS and NRAS) has been
validated for treatment personalization in advanced colorectal
cancer through the support of several studies [21]. Similar to RAS
genes, BRAF also encodes proteins that act in the RAS-RAF-
MAPK signalling pathway and may be involved in resistance to
anti-EGFR treatment. However, these initial observations were
often conflicting and limited to a small proportion of patients. For
example, preliminary data on the role of BRAF status seemed
promising for a straightforward application in clinical practice
[22], but a large subsequent analysis from the CRYSTAL
(‘‘Cetuximab Combined With Irinotecan in First-line Therapy
for Metastatic Colorectal Cancer’’) fist-line trial demonstrated that
BRAF mutation is a poor prognostic factor, but not a predictive
one [23]. It was also demonstrated that, similarly to what observed
for the oncogenic activation of the MAPK pathway, the
constitutive deregulation of the PI3KCA could bypass the EGFR
signaling pathway and be responsible of clinical resistance [13]. A
previous systematic review found that PI3KCA exon 20 mutations
was associated with a lower response rate, shorter progression-free
survival and overall survival and thus may be a potential
biomarker for resistance to anti-EGFR monoclonal antibodies in
KRAS wild-type metastatic CRC, whereas PI3KCA exon 9
mutations seemed to have no such role [24].
Figure 2. Flow-chart of patients population.
doi:10.1371/journal.pone.0092147.g002
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Since the response rate to cetuximab is 41,2% in patients with
‘‘quadruple wild-type’’ tumors [7], it is evident that other
biomarkers must be involved in treatment primary resistance.
Alterations of membrane tyrosine kinase receptors ‘‘competing’’
with EGFR – such as HER-3, MET or IGFR - might play a role
in treatment refractoriness, due to cross-talk in signalling
downstream [25–27]. Despite the relevant number of preclinical
observations, few clinical studies have been conducted to explore
the putative function of growth factor receptor interdependence
and complementarity in influencing clinical outcome with anti-
EGFR treatment. Moreover, results in this research field often
have been contradictory and not easily transferable to clinical
practice. In fact, previous studies in this setting may have
significant biases due to analysis of series with retrospectively-
identified subgroups and inclusion of RAS, BRAF and PI3KCA
mutant tumors. This may significantly affect the results, as the
small sample size could have been clearly statistically inadequate
for multiple comparisons of concomitant factors.
Recently, ALK translocation have been reported in about 2.5%
of CRC characterized by C2orf44-ALK and EML4-ALK gene
fusions [28,29]. However, other ALK fusion partners have been
described in non-small cell lung cancer and other tumor types,
limiting the possibility to found all ALK translocations that may be
present in CRC specimens. Moreover, signal enumeration in solid
tumour sections by FISH is challenging to interpret and guidelines
for analytical methods and scoring systems are not available for
CRC, partly explaining why ALK gene copy number as biomarker
has not been extensively investigated yet. Regarding the role of
ALK in the development and progression of CRC, a recent study
by Aisner et al. found marked intratumoral heterogeneity for both
KRAS mutation and ALK rearrangement in CRC and in region
of high-grade dysplasia [30]. Authors suggest as this evidence may
create the basis for several hypotheses explaining mechanisms by
which combinations of KRAS and ALK status might exist through
clonal cancer evolution [30]. Regarding the prognostic role of
ALK, the association between copy number alterations and
clinical outcome was not extensively studied in CRC. Recently,
the increase of ALK gene copy number was recognized as an
independent poor prognostic factor in a retrospective series of 770
patients with CRC [31]. ALK gene copy number (amplification/
gain) was found out only in 3.4% of all CRC samples studied,
possibly reflecting the relatively low number of stage IV patients
included and due to the statistically significant association of ALK
copy number alterations with more advanced disease stage [31].
To our knowledge, our study is the first to investigate the role of
ALK as a prognostic factor in patients with advanced CRC
receiving cetuximab or panitumumab. In our analysis, the
subgroup of patients with chemorefractory CRC and increased
ALK gene copy number had ha significantly lower likelihood to
respond to anti-EGFR treatment, despite a RAS-RAF-PI3KCA
wild-type status. ALK status seemed to influence only the response
rate and PFS, but not OS duration, thus limiting the rationale for
its use as a prognostic factor. However, it must be pointed out that
potential differences of OS according to ALK status may have
been confounded by post-progression treatments usually pre-
scribed at our tertiary cancer center – including chemotherapy
rechallenge, regorafenib, anti-EGFR rechallenge, temozolomide
in MGMT methylated tumors and molecular profiling for
Table 1. Patients demographics and disease characteristics.
Main characteristics Number (%)
Age, median (range) 65 (36–81) years
Gender
Male 38 (56)
Female 30 (44)
ECOG performance status
0 44 (65)
1 24 (35)
Primary tumour site
Right colon 15 (22)
Left colon 24 (35)
Rectum 29 (43)
Stage IV presentation
Synchronous 45 (66)
Metachronous 23 (34)
Sites of disease
1 22 (32)
$2 46 (68)
Treatment
Irinotecan - cetuximab 44 (65)
Panitumumab 24 (35)
doi:10.1371/journal.pone.0092147.t001
Figure 3. Progression-free survival analysis. Kaplan-Meier curves
for progression-free survival according to ALK status: increase of gene
copy number vs. disomic status.
doi:10.1371/journal.pone.0092147.g003
Figure 4. Overall survival analysis. Kaplan-Meier curves for overall
survival according to ALK status: increase of gene copy number vs.
disomic status.
doi:10.1371/journal.pone.0092147.g004
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inclusion in phase I trials with targeted agents [32–34].
Furthermore, the small sample size and the lack of a control
group of our study leave open the possibility that ALK copy
number alterations may be a prognostic factor rather than a
predictive one, since there is no way to dissect the predictive from
prognostic significance. In fact, the possible predictive role of ALK
gene status as key pathway of resistance to anti-EGFR treatment
needs to be further confirmed through adequately powered,
randomized studies. However, despite some intrinsic limitations,
patients included in this analysis were obtained from a prospective
database and were treated homogeneously with anti-EGFR
monoclonal antibodies for chemorefractory disease. All patients
were selected through a ‘‘molecular enrichment’’ process – and
those with possible confounding RAS, BRAF, and/or PI3KCA
mutations were considered ineligible.
Finally, whether high ALK gene copy number may represent a
true predictive factor of response to ALK inhibitors was not
studied in CRC. Interestingly, ALK may be a possible molecular
target as part of a treatment protocol focused on control of either
EGFR and ALK receptors, or the PI3KCA pathway. The
possibility of using ALK inhibitors in biologically selected anti–
EGFR-resistant tumors promises to be a crucial challenge for the
future development of targeted therapy in CRC patients. The lack
of ALK translocated cases, together with the low percentage of
cells with amplification in all cases, suggests that gain of gene copy
number might not be a biologically relevant event or predict
response to ALK targeting molecules. Furthermore, ALK gene
copy gain may be associated with copy number aberration of other
competing genes, such as MET or EGFR itself [35,36].
Nevertheless, these observations do not definitely rule out the
potential benefit of ALK inhibitors in this population, as
demonstrated in colorectal patients without EGFR protein
expression that do respond to therapeutic monoclonal antibodies
targeting EGFR [37].
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